香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 BrainAurora Medical Technology Limited 腦動極光醫療科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6681） 自願公告 訂立戰略合作協議以拓展新加坡市場及推動國際化佈局 本公告為腦動極光醫療科技有限公司（「本公司」，連同其附屬公司統稱「本集團」） 自願發佈的公告，目的是使廣大投資者瞭解本集團最新業務發展情況。 根據協議，雙方合作主要包括以下內容：(I)產品推廣合作：本公司負責認知障礙 數字療法產品在新加坡的本土化適配、系統落地及人員培訓支持；萊賀思寶將依 託其全部線下門店及會員資源，向目標用戶定向推薦本公司產品，並負責全流程 服務，包括產品介紹、試用引導、購買轉化及售後支持。(II)市場拓展協同：雙方 整合產品、渠道、品牌與技術等資源，共同開拓新加坡市場，重點推動本公司產 品進入新加坡頭部私立醫院及公立醫院體系，提升產品在當地醫療系統中的應用 與普及。 ...

Core Viewpoint - The report highlights that Health 160 (2656.HK), a leading digital healthcare platform in China, is approaching a profitability inflection point, driven by its unique resource endowment and value reassessment, with a "Buy" rating and a target price of HKD 90.54 [1] Group 1: Company Overview - Health 160 is recognized as a top digital healthcare service platform in China, with over 18 years of industry experience, leading in key resource metrics such as appointment volume and the number of partnered medical institutions and healthcare professionals [1] - The company has established strong "resource + user" dual barriers, positioning itself favorably in the market [1] Group 2: Financial Performance - The company has shown clear signs of a performance inflection point, with revenue returning to a growth trajectory and adjusted net losses significantly narrowing, indicating a path towards profitability [1] - Revenue projections for 2025-2027 are estimated at CNY 674 million, CNY 775 million, and CNY 930 million, with growth rates of 8%, 15%, and 20% respectively [2] - Net profit forecasts for the same period are CNY 12 million, CNY 36 million, and CNY 90 million, reflecting a gradual improvement in financial health [2] Group 3: Business Model and Growth Drivers - The business operates on a dual-driven model consisting of "pharmaceutical product distribution" and "digital health services," supported by a localized network covering over 260 cities [1] - The company is benefiting from the high growth potential of the digital healthcare industry, with a unique platform value and a clear path to profitability, suggesting a critical value reassessment from "loss reduction" to "profitability" [1]

来源：格隆汇APP 格隆汇12月22日丨脑动极光-B(6681.HK)午后持续拉升涨超19%报7.02港元；消息面上，公司公告参与国 家科技重大专项研究课题及获批认知障碍数字医疗北京市重点实验室。 ...

公告称，本次启动的国家科技重大专项，聚焦ICAS相关认知障碍的诊疗难题，依托多学科交叉优势开 展系统性研究，核心方向包括建立ICAS相关认知障碍的评估技术体系及深度推理预测大模型，以提供 疾病早期筛查、风险预判和预防、干预的诊疗工具，并建立ICAS相关认知障碍全场景闭环管理体系。 本文源自：智通财经网 本项目已于近期正式启动。同时，智精灵科技与首都医科大学宣武医院(宣武医院)等联合申报的"认知 障碍数字医疗北京市重点实验室"亦已于近日正式获批成立。 智通财经获悉，脑动极光-B(06681)涨超5%，截至发稿，涨5.09%，报6.18港元，成交额1666.49万港 元。 消息面上，12月22日，脑动极光-B发布公告，公司旗下全资附属公司北京智精灵科技有限公司(智精灵 科技)作为重要合作单位，共同参与国家科技重大专项"癌症、心脑血管、呼吸和代谢性疾病防治研 究"项目，课题名称为《基于深度推理大模型的颅内动脉粥样硬化狭窄相关认知障碍数字诊疗关键技术 建立及场景化应用》(国家科技重大专项)。 ...

Core Viewpoint - Brainstorm Aurora-B (06681) has seen a stock price increase of over 5%, currently trading at 6.18 HKD with a transaction volume of 16.66 million HKD, following the announcement of its participation in a significant national technology project focused on the prevention and treatment of various diseases, including cognitive disorders related to intracranial atherosclerosis [1] Group 1: Company Developments - The company announced that its wholly-owned subsidiary, Beijing Zhijingling Technology Co., Ltd. (Zhijingling Technology), is a key partner in the national technology major project titled "Research on the Prevention and Treatment of Cancer, Cardiovascular, Respiratory, and Metabolic Diseases" [1] - The project, which has recently been officially launched, aims to address diagnostic challenges related to cognitive disorders associated with intracranial atherosclerosis (ICAS) [1] - Zhijingling Technology, in collaboration with Xuanwu Hospital of Capital Medical University, has also successfully established the "Beijing Key Laboratory of Digital Medical for Cognitive Disorders" [1] Group 2: Project Focus and Objectives - The national technology major project focuses on the diagnostic challenges of ICAS-related cognitive disorders, leveraging interdisciplinary advantages for systematic research [1] - Key objectives include the establishment of an assessment technology system for ICAS-related cognitive disorders and the development of a deep reasoning predictive model to provide early screening, risk assessment, prevention, and intervention tools [1] - The project aims to create a comprehensive management system for ICAS-related cognitive disorders, ensuring a closed-loop management approach across various scenarios [1]

Core Viewpoint - Brain Dynamics Aurora-B (06681) has announced its participation in a significant national science and technology project focused on the prevention and treatment of diseases such as cancer, cardiovascular, respiratory, and metabolic diseases, specifically targeting cognitive disorders related to intracranial atherosclerosis [2][5]. Group 1 - The company's stock price increased by 6.62%, currently trading at 6.28 HKD with a transaction volume of 34.81 million HKD [2][5]. - The project, titled "Establishment of Key Technologies for Digital Diagnosis and Treatment of Cognitive Disorders Related to Intracranial Atherosclerosis," has officially commenced [2][5]. - The project aims to develop a comprehensive assessment technology system and deep reasoning predictive model for cognitive disorders associated with intracranial atherosclerosis, providing tools for early disease screening, risk assessment, prevention, and intervention [2][5]. Group 2 - The establishment of the "Beijing Key Laboratory for Digital Medical Treatment of Cognitive Disorders," in collaboration with Capital Medical University Xuanwu Hospital, has also been officially approved [2][5]. - The project leverages interdisciplinary advantages to conduct systematic research on the diagnostic challenges of cognitive disorders related to ICAS [2][5]. - The initiative will create a closed-loop management system for cognitive disorders associated with ICAS [2][5].

脑动极光-B(06681)发布公告，公司旗下全资附属公司北京智精灵科技有限公司(智精灵科技)作为重要合 作单位，共同参与国家科技重大专项"癌症、心脑血管、呼吸和代谢性疾病防治研究"项目，课题名称为 《基于深度推理大模型的颅内动脉粥样硬化狭窄相关认知障碍数字诊疗关键技术建立及场景化应用》 (项目编号：2025ZD0546200)(国家科技重大专项)。本项目已于近期正式启动。同时，智精灵科技与首 都医科大学宣武医院(宣武医院)等联合申报的"认知障碍数字医疗北京市重点实验室"亦已于近日正式获 批成立。 本次启动的国家科技重大专项，聚焦ICAS相关认知障碍的诊疗难题，依托多学科交叉优势开展系统性 研究，核心方向包括建立ICAS相关认知障碍的评估技术体系及深度推理预测大模型，以提供疾病早期 筛查、风险预判和预防、干预的诊疗工具，并建立ICAS相关认知障碍全场景闭环管理体系。 本项目的实施旨在建立国际领先的ICAS相关认知障碍诊疗技术体系，构建符合中国国情的疾病管理模 式，有效预防与延缓疾病进展，助力"健康中国"战略。本项目由宣武医院牵头，联合中国医学科学院北 京协和医院、中国科学院心理研究所、吉林大学、北京师範大学及智 ...

Core Viewpoint - The company, through its subsidiary Beijing Zhijingling Technology Co., Ltd., is participating in a national major science and technology project focused on the diagnosis and treatment of cognitive disorders related to intracranial atherosclerotic stenosis (ICAS) [1][2][3] Group 1: Project Overview - The national major science and technology project aims to address the diagnostic challenges of ICAS-related cognitive disorders by developing a comprehensive assessment technology system and deep reasoning predictive models [2] - The project is led by Xuanwu Hospital and involves collaboration with several prestigious institutions, including the Chinese Academy of Medical Sciences and Jilin University, bringing together top experts from neurology, cognitive neuroscience, psychology, and artificial intelligence [2][3] Group 2: Company Role and Contributions - The company will leverage its expertise in digital diagnosis and treatment of neurological and psychiatric disorders to develop deep reasoning models and digital treatment platforms for ICAS-related cognitive disorders [3] - The newly established Beijing Key Laboratory for Digital Therapy of Cognitive Disorders will integrate clinical medicine, basic research, technology development, and hardware innovation, with the company playing a key role in algorithm development and user experience optimization [3]

格隆汇12月22日丨脑动极光-B(06681.HK)宣布，公司旗下全资附属公司北京智精灵科技有限公司("智精 灵科技")作为重要合作单位，共同参与国家科技重大专项"癌症、心脑血管、呼吸和代谢性疾病防治研 究"项目，课题名称为《基于深度推理大模型的颅内动脉粥样硬化狭窄相关认知障碍数字诊疗关键技术 建立及场景化应用》(项目编号：2025ZD0546200)("本项目")或("国家科技重大专项")。本项目已于近期 正式启动。同时，智精灵科技与首都医科大学宣武医院("宣武医院")等联合申报的"认知障碍数字医疗北 京市重点实验室"亦已于近日正式获批成立。 公司所承担的国家科技重大专项及获批北京市重点实验室，均充分彰显了公司在认知障碍数字诊疗领域 的技术引领地位。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 BrainAurora Medical Technology Limited 腦動極光醫療科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6681） 本次啟動的國家科技重大專項，聚焦ICAS相關認知障礙的診療難題，依託多 學科交叉優勢開展系統性研究，核心方向包括建立ICAS相關認知障礙的評估 技術體系及深度推理預測大模型，以提供疾病早期篩查、風險預判和預防、 干預的診療工具，並建立ICAS相關認知障礙全場景閉環管理體系。 本項目的實施旨在建立國際領先的ICAS相關認知障礙診療技術體系，構建符 合中國國情的疾病管理模式，有效預防與延緩疾病進展，助力「健康中國」戰 略。本項目由宣武醫院牽頭，聯合中國醫學科學院北京協和醫院、中國科學 院心理研究所、吉林大學、北京師範大學及智精靈科技等單位共同攻關。研 究團隊匯集了神經病學、認知神經科學、心理學與人工智能等領域的頂尖專 家，並與國際領先研究團隊保持長 ...